The Experts below are selected from a list of 246 Experts worldwide ranked by ideXlab platform
Gregory C. Allen - One of the best experts on this subject based on the ideXlab platform.
-
Malignant Hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American Malignant Hyperthermia registry of the Malignant Hyperthermia association of the United States.
Anesthesia and analgesia, 2014Co-Authors: Marilyn Green Larach, Barbara W. Brandom, Gregory C. Allen, Gerald A. Gronert, Erik LehmanAbstract:BACKGROUND:AMRA (adverse metabolic or muscular reaction to anesthesia) reports submitted to The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States from 1987 to 2006 revealed a 2.7% cardiac arrest and a 1.4% death rate for 291 Malignant hyper
-
The Epidemiology of Malignant Hyperthermia Events in North America
Malignant Hyperthermia, 1996Co-Authors: Marilyn Green Larach, Linda J. Fuhrmann, Gregory C. AllenAbstract:This chapter presents preliminary data drawn from the North American Malignant Hyperthermia Registry concerning the epidemiology of Malignant Hyperthermia (MH) events in North America.
-
Malignant Hyperthermia and associated disorders.
Current opinion in rheumatology, 1993Co-Authors: Gregory C. AllenAbstract:Malignant Hyperthermia is a pharmacogenetic disorder of skeletal muscle that may cause a life-threatening reaction during administration of general anesthesia. It is inherited in an autosomal dominant pattern and, at least in some families, is caused by a mutation in the ryanodine receptor-calcium-release channel gene on chromosome 19. Malignant Hyperthermia displays heterogeneity, making the development of a simple screening test difficult. Malignant Hyperthermia may be caused by other biochemical defects affecting intramyoplasmic calcium. Some myopathies, such as central core disease, are frequently associated with Malignant Hyperthermia susceptibility. In other myopathies, like Duchenne muscular dystrophy, unusual compensatory mechanisms may produce a hypermetabolic state identical to that of Malignant Hyperthermia.
Joseph R. Tobin - One of the best experts on this subject based on the ideXlab platform.
-
Malignant Hyperthermia: human stress triggering.
Biochimica et biophysica acta, 2011Co-Authors: Gerald A. Gronert, Joseph R. Tobin, Sheila M. MuldoonAbstract:Letter to the Editor concerns the question of a discussion of awake porcine Malignant Hyperthermia that erroneously omits the awake human stress reaction of Malignant Hyperthermia.
-
postoperative Malignant Hyperthermia an analysis of cases from the north american Malignant Hyperthermia registry
Anesthesiology, 2008Co-Authors: Ronald S. Litman, Christopher Flood, Richard F Kaplan, Yung Ly Kim, Joseph R. TobinAbstract:Background: The initial presentation of Malignant Hyperthermia (MH) may begin in the postoperative period. However, the maximal latency period between the end of anesthesia care and the onset of postoperative MH is unknown. The authors hypothesized that this latency period is short and is not manifested by Hyperthermia as the initial presenting sign. The authors sought to test this hypothesis and to describe the clinical characteristics of postoperative MH by analysis of suspected cases in the North American Malignant Hyperthermia Registry. Methods: Of 528 possible or suspected cases of MH in the North American Malignant Hyperthermia Registry, the authors identified 64 possible reports of postoperative MH. The records were reviewed in detail by the authors, each of whom assigned a qualitative score of "likely," "not likely," "not enough information available," or "not applicable" (where MH was not the final definitive diagnosis). Postoperative MH was confirmed after a consensus meeting of the three senior authors who reviewed in detail all possible "likely" cases. Results: The authors identified postoperative MH in 10 subjects. All received volatile agents and 5 also received succinylcholine. All demonstrated signs characteristic of acute MH, including generalized rigidity, hypercapnia and/or tachypnea, tachycardia, and Hyperthermia. No subject demonstrated Hyperthermia as the presenting sign. The latency period between the anesthesia finish time and the onset of a sign indicative of acute MH ranged from 0 to 40 min. Conclusions: Postoperative MH is uncommon, occurring in 10 of 528 suspected MH cases (1.9%) reported to the North American Malignant Hyperthermia Registry. Postoperative MH began shortly after completion of the anesthetic care. Hyperthermia was not a presenting sign of MH.
Barbara W. Brandom - One of the best experts on this subject based on the ideXlab platform.
-
Malignant Hyperthermia--AN UPDATE FOR PERIOPERATIVE NURSES.
ORNAC journal, 2015Co-Authors: Sheila Riazi, Barbara W. BrandomAbstract:This article is a summary of the "Updates on Malignant Hyperthermia" presentation given at the 2015 ORNAC National Conference in Edmonton. It presents the facts known about Malignant Hyperthermia (MH) including definition, anesthetic and non-anesthetic triggers for MH, signs and symptoms, and treatment of MH. It also discusses the care of an MH susceptible patient while undergoing an elective surgery.
-
Malignant Hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American Malignant Hyperthermia registry of the Malignant Hyperthermia association of the United States.
Anesthesia and analgesia, 2014Co-Authors: Marilyn Green Larach, Barbara W. Brandom, Gregory C. Allen, Gerald A. Gronert, Erik LehmanAbstract:BACKGROUND:AMRA (adverse metabolic or muscular reaction to anesthesia) reports submitted to The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States from 1987 to 2006 revealed a 2.7% cardiac arrest and a 1.4% death rate for 291 Malignant hyper
-
Ambulatory surgery and Malignant Hyperthermia.
Current opinion in anaesthesiology, 2009Co-Authors: Barbara W. BrandomAbstract:Purpose of review It is timely to review recent publications that add to our knowledge of Malignant Hyperthermia because we can go to the web or to newspapers and read of recent tragic Malignant Hyperthermia deaths. Recent findings New methods were used to affirm some of the previous observations regarding the epidemiology of Malignant Hyperthermia, and the well known North American Malignant Hyperthermia Registry was used to describe characteristics of Malignant Hyperthermia deaths. Anesthesia workstations have been found to have a larger reservoir of potent inhalation anesthetics than did their predecessors. Activated charcoal can assist in cleaning these machines. Genetic diagnosis of Malignant Hyperthermia susceptibility can sometimes be obtained from blood specimens. Work continues to increase the sensitivity of blood-based testing of Malignant Hyperthermia susceptibility. Summary Because Malignant Hyperthermia is potentially lethal, families should be evaluated as thoroughly as possible when an individual who claims to be Malignant Hyperthermia susceptible presents for elective surgery. Genetic testing may facilitate the evaluation of families with a very strong history of Malignant Hyperthermia. The use of activated charcoal can speed the removal of potent inhalation anesthetics from anesthesia workstations. This should facilitate the anesthetic care of Malignant Hyperthermia susceptible patients.
-
Genetics of Malignant Hyperthermia.
TheScientificWorldJournal, 2006Co-Authors: Barbara W. BrandomAbstract:Study of the genetics of the Malignant Hyperthermia syndrome began in families in which both Malignant Hyperthermia (MH) episodes had been experienced and individuals had strongly positive contracture tests diagnostic of susceptibility to MH. Linkage studies associated this MH phenotype to the ryanodine receptor gene (RYR1) at chromosome 19q13.1 in many families. Although the MH phenotype is not always linked to chromosome 19, the RYR1 has remained the focus of experimentation. Other candidate genes exist, but few MH-susceptible families have variants of these genes. Hundreds of MH-susceptible people have variants of RYR1.
Ronald S. Litman - One of the best experts on this subject based on the ideXlab platform.
-
Malignant Hyperthermia Susceptibility and Related Diseases.
Anesthesiology, 2018Co-Authors: Ronald S. Litman, Sarah M. Griggs, James J. Dowling, Sheila RiaziAbstract:This review identifies disease states associated with Malignant Hyperthermia susceptibility based on genotypic and phenotypic findings, and a framework is established for clinicians to identify a potentially Malignant Hyperthermia–susceptible patient.
-
postoperative Malignant Hyperthermia an analysis of cases from the north american Malignant Hyperthermia registry
Anesthesiology, 2008Co-Authors: Ronald S. Litman, Christopher Flood, Richard F Kaplan, Yung Ly Kim, Joseph R. TobinAbstract:Background: The initial presentation of Malignant Hyperthermia (MH) may begin in the postoperative period. However, the maximal latency period between the end of anesthesia care and the onset of postoperative MH is unknown. The authors hypothesized that this latency period is short and is not manifested by Hyperthermia as the initial presenting sign. The authors sought to test this hypothesis and to describe the clinical characteristics of postoperative MH by analysis of suspected cases in the North American Malignant Hyperthermia Registry. Methods: Of 528 possible or suspected cases of MH in the North American Malignant Hyperthermia Registry, the authors identified 64 possible reports of postoperative MH. The records were reviewed in detail by the authors, each of whom assigned a qualitative score of "likely," "not likely," "not enough information available," or "not applicable" (where MH was not the final definitive diagnosis). Postoperative MH was confirmed after a consensus meeting of the three senior authors who reviewed in detail all possible "likely" cases. Results: The authors identified postoperative MH in 10 subjects. All received volatile agents and 5 also received succinylcholine. All demonstrated signs characteristic of acute MH, including generalized rigidity, hypercapnia and/or tachypnea, tachycardia, and Hyperthermia. No subject demonstrated Hyperthermia as the presenting sign. The latency period between the anesthesia finish time and the onset of a sign indicative of acute MH ranged from 0 to 40 min. Conclusions: Postoperative MH is uncommon, occurring in 10 of 528 suspected MH cases (1.9%) reported to the North American Malignant Hyperthermia Registry. Postoperative MH began shortly after completion of the anesthetic care. Hyperthermia was not a presenting sign of MH.
Albert Urwyler - One of the best experts on this subject based on the ideXlab platform.
-
Availability of dantrolene for the management of Malignant Hyperthermia crises: European Malignant Hyperthermia Group guidelines.
British journal of anaesthesia, 2020Co-Authors: Klaus Peter Egede Glahn, Stephan Johannsen, Philip M. Hopkins, H. Rüffert, Thierry Girard, Diana Bendixen, Marc M J Snoeck, Albert UrwylerAbstract:Summary Faced with a Malignant Hyperthermia crisis, the immediate access to sufficient dantrolene is essential to achieve the best possible outcome for the patient. However, Malignant Hyperthermia crises are rare, and there may be administrative pressures to limit the amount of dantrolene stocked or, in some countries, not to stock dantrolene at all. There are no published guidelines to support anaesthetic departments in their effort to ensure availability of sufficient dantrolene for the management of Malignant Hyperthermia crises. After a literature review that confirmed a lack of clinical trials to inform this guideline, we undertook a formal consensus development process, in which 25 members of the European Malignant Hyperthermia Group participated. The consensus process used a modified web-based Delphi exercise, in which participants rated the appropriateness of statements that covered the dosing regimen for dantrolene in a Malignant Hyperthermia crisis, the types of facility that should stock dantrolene, and the amount of dantrolene that should be stocked. The resulting guidelines are based on available evidence and the opinions of international Malignant Hyperthermia experts representing a large group of Malignant Hyperthermia laboratories from around the world. Key recommendations include: the dosing regimen of dantrolene should be based on actual body weight, dantrolene should be available wherever volatile anaesthetics or succinylcholine are used, and 36 vials of dantrolene should be immediately available with a further 24 vials available within 1 h.
-
European Malignant Hyperthermia Group guidelines for investigation of Malignant Hyperthermia susceptibility
British journal of anaesthesia, 2015Co-Authors: Philip M. Hopkins, Klaus Peter Egede Glahn, H. Rüffert, M. Snoeck, Thierry Girard, F.r. Ellis, Clemens R. Müller, Albert UrwylerAbstract:It is 30 yr since the British Journal of Anaesthesia published the first consensus protocol for the laboratory diagnosis of Malignant Hyperthermia susceptibility from the European Malignant Hyperthermia Group. This has subsequently been used in more than 10 000 individuals worldwide to inform use of anaesthetic drugs in these patients with increased risk of developing Malignant Hyperthermia during general anaesthesia, representing an early and successful example of stratified medicine. In 2001, our group also published a guideline for the use of DNA-based screening of Malignant Hyperthermia susceptibility. We now present an updated and complete guideline for the diagnostic pathway for patients potentially at increased risk of developing Malignant Hyperthermia. We introduce the new guideline with a narrative commentary that describes its development, the changes to previously published protocols and guidelines, and new sections, including recommendations for patient referral criteria and clinical interpretation of laboratory findings.
-
recognizing and managing a Malignant Hyperthermia crisis guidelines from the european Malignant Hyperthermia group
BJA: British Journal of Anaesthesia, 2010Co-Authors: Klaus Peter Egede Glahn, F.r. Ellis, Clemens R. Müller, Albert Urwyler, Marc M J Snoeck, P J Halsall, F WapplerAbstract:Survival from a Malignant Hyperthermia (MH) crisis is highly dependent on early recognition and prompt action. MH crises are very rare and an increasing use of total i.v. anaesthesia is likely to make it even rarer, leading to the potential risk of reduced awareness of MH. In addition, dantrolene, the cornerstone of successful MH treatment, is unavailable in large areas around the world thereby increasing the risk of MH fatalities in these areas. The European Malignant Hyperthermia Group collected and reviewed all guidelines available from the various MH centres in order to provide a consensus document. The guidelines consist of two textboxes: Box 1 on recognizing MH and Box 2 on the treatment of an MH crisis.